DE3733478A1
(de)
*
|
1987-10-01 |
1989-04-13 |
Schering Ag |
Antigestagen- und antioestrogenwirksame verbindungen zur geburtseinleitung und zum schwangerschaftsabbruch sowie zur behandlung gynaekologischer stoerungen und hormonabhaengiger tumore
|
EP0310542B1
(de)
*
|
1987-10-01 |
1994-06-08 |
Schering Aktiengesellschaft |
Antigestagen- und antiöstrogenwirksame Verbindungen zur Behandlung hormonabhängiger Tumoren
|
US4895715A
(en)
*
|
1988-04-14 |
1990-01-23 |
Schering Corporation |
Method of treating gynecomastia
|
GB8813353D0
(en)
*
|
1988-06-06 |
1988-07-13 |
Ici Plc |
Therapeutic product
|
US5393785A
(en)
*
|
1988-10-31 |
1995-02-28 |
Endorecherche, Inc. |
Therapeutic antiestrogens
|
US5204337A
(en)
*
|
1988-10-31 |
1993-04-20 |
Endorecherche Inc. |
Estrogen nucleus derivatives for use in inhibition of sex steroid activity
|
HU208150B
(en)
*
|
1988-10-31 |
1993-08-30 |
Endorecherche Inc |
Process for producing new estrogen derivatives having steroid hormone inhibitor activity and pharmaceutical compositions comprising such derivatives
|
US5395842A
(en)
*
|
1988-10-31 |
1995-03-07 |
Endorecherche Inc. |
Anti-estrogenic compounds and compositions
|
US5686465A
(en)
*
|
1988-10-31 |
1997-11-11 |
Endorecherche Inc. |
Sex steroid activity inhibitors
|
FR2643638B1
(fr)
*
|
1989-02-24 |
1991-06-14 |
Roussel Uclaf |
Nouveaux 19-nor steroides ayant en position 11beta une chaine carbonee comportant une fonction amide ou carbamate, leur procede de preparation et les intermediaires de ce procede, leur application comme medicaments et les compositions pharmaceutiques les contenant
|
US5372996A
(en)
*
|
1989-03-10 |
1994-12-13 |
Endorecherche, Inc. |
Method of treatment of androgen-related diseases
|
US5364847A
(en)
*
|
1989-03-10 |
1994-11-15 |
Endorecherche |
Inhibitors of sex steroid biosynthesis and methods for their production and use
|
HU221589B
(hu)
*
|
1989-03-10 |
2002-11-28 |
Endorecherche Inc. |
Emlő- és méhrák kezelésére alkalmas kombinációs gyógyszerkészítmény és eljárás előállítására
|
WO1991000732A1
(en)
*
|
1989-07-07 |
1991-01-24 |
Endorecherche Inc. |
Androgen derivatives for use in the inhibition of sex steroid activity
|
CA2062792C
(en)
*
|
1989-07-07 |
2006-03-21 |
Fernard Labrie |
Treatment of androgen-related diseases
|
DE3925507A1
(de)
*
|
1989-07-28 |
1991-01-31 |
Schering Ag |
14,17(alpha)-etheno- und ethanoestratriene, verfahren zur herstellung dieser verbindungen, sowie ihre verwendung zur herstellung von arzneimitteln
|
FR2654337B1
(fr)
*
|
1989-11-15 |
1994-08-05 |
Roussel Uclaf |
Nouvelles microspheres injectables biodegradables procede de preparation et suspensions injectables les renfermant.
|
ZA924811B
(en)
*
|
1991-06-28 |
1993-12-29 |
Endorecherche Inc |
Controlled release systems and low dose androgens
|
US6060503A
(en)
*
|
1991-12-02 |
2000-05-09 |
Endorecherche, Inc. |
Benzopyran-containing compounds and method for their use
|
UA35589C2
(uk)
*
|
1992-05-21 |
2001-04-16 |
Андорешерш Інк. |
ІНГІБІТОРИ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ІНГІБУВАННЯ АКТИВНОСТІ ТЕСТОСТЕРОН 5-<font face="Symbol">a</font>-РЕДУКТАЗИ
|
DE19622457A1
(de)
*
|
1996-05-24 |
1997-11-27 |
Schering Ag |
7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US5866560A
(en)
|
1996-08-20 |
1999-02-02 |
Schering Ag |
7α-(ξ-aminoalkyl)-estratrienes, process for their production, pharmaceutical preparations which contain these 7α-(ξ-aminoalkyl)-estratrienes as well as their use for the production of pharmaceutical agents
|
DE19635525A1
(de)
*
|
1996-08-20 |
1998-02-26 |
Schering Ag |
7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
|
EP1025116A1
(de)
*
|
1997-10-23 |
2000-08-09 |
American Home Products Corporation |
Oestra-1,3,5(10)-trien-7alpha-thioether
|
US6355630B1
(en)
|
1997-10-23 |
2002-03-12 |
American Home Products Corporation |
Estra-1,3,5(10)-triene-7α-thioethers
|
PE20000129A1
(es)
*
|
1997-12-23 |
2000-03-11 |
Schering Ag |
11 beta-halogeno-estratrienos sustituidos en 7 alfa, asi como el procedimiento para elaborar preparados farmaceuticos que contienen tales 11 beta-halogeno-estratrienos sustituidos en 7 alfa
|
DE19807791A1
(de)
|
1998-02-19 |
1999-08-26 |
Schering Ag |
Kombinationspräparat aus Östrogen und Antiöstrogen
|
CA2330611A1
(en)
|
1998-05-22 |
1999-12-02 |
The Board Of Trustees Of The Leland Stanford Junior University |
Bifunctional molecules and therapies based thereon
|
GB0000313D0
(en)
|
2000-01-10 |
2000-03-01 |
Astrazeneca Uk Ltd |
Formulation
|
DE10027887A1
(de)
*
|
2000-05-31 |
2001-12-13 |
Jenapharm Gmbh |
Verbindungen mit einer Sulfonamidgruppe und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
|
JP3908162B2
(ja)
|
2000-06-30 |
2007-04-25 |
中外製薬株式会社 |
新規な抗アンドロゲン剤
|
GB0025221D0
(en)
|
2000-10-14 |
2000-11-29 |
Astrazeneca Ab |
New process
|
US20050084908A1
(en)
*
|
2000-11-06 |
2005-04-21 |
Chugai Seiyaku Kabushiki Kaisha |
Methods for detecting binding of low-molecular-weight compound and its binding partner molecule
|
NZ527692A
(en)
|
2001-02-19 |
2005-05-27 |
Novartis Ag |
Cancer treatment
|
SI1392313T1
(sl)
|
2001-05-16 |
2007-08-31 |
Novartis Ag |
Kombinacija, ki vkljuäśuje n-5-4-(4-metil-piperazino-metil)-benzoilamido/-2-metilfenil-4-(3- piridil)-2pirimidin-amin in difosfonat
|
GB0123961D0
(en)
*
|
2001-10-05 |
2001-11-28 |
Astrazeneca Ab |
Process and intermediates
|
DE10159217A1
(de)
|
2001-11-27 |
2003-06-05 |
Schering Ag |
17alpha-Alkyl-17ß-oxy-estratriene und Zwischenprodukte zu deren Herstellung, Verwendung der 17alpha-Alkyl-17ß-oxy-estratriene zur Herstellung von Arzneimitteln sowie pharmazeutische Präparate
|
GB0128510D0
(en)
*
|
2001-11-28 |
2002-01-23 |
Novartis Ag |
Organic compounds
|
CA2483594C
(en)
|
2002-05-16 |
2011-02-15 |
Novartis Ag |
Use of edg receptor binding agents in cancer
|
CA2484000A1
(en)
|
2002-05-24 |
2003-12-04 |
Schering Corporation |
Neutralizing human anti-igfr antibody
|
PE20050928A1
(es)
*
|
2003-11-21 |
2005-11-08 |
Schering Corp |
Combinaciones terapeuticas de anticuerpo anti-igfr1
|
CA2560162C
(en)
|
2004-04-07 |
2013-05-21 |
Novartis Ag |
Inhibitors of iap
|
CN100395259C
(zh)
*
|
2004-04-28 |
2008-06-18 |
江苏豪森药业股份有限公司 |
甾体类衍生物
|
US7534780B2
(en)
*
|
2004-05-21 |
2009-05-19 |
Bayer Schering Pharma Aktiengesellschaft |
Estradiol prodrugs
|
US20050277625A1
(en)
*
|
2004-05-21 |
2005-12-15 |
Ralf Wyrwa |
Estriol and estetrol prodrugs
|
GB0512324D0
(en)
|
2005-06-16 |
2005-07-27 |
Novartis Ag |
Organic compounds
|
ATE482966T1
(de)
*
|
2004-07-27 |
2010-10-15 |
Sicor Inc |
Verfahren zur herstellung von 7-alpha-alkylierte 19-norsteroide
|
ES2552338T3
(es)
|
2005-01-21 |
2015-11-27 |
Astex Therapeutics Limited |
Compuestos farmacéuticos
|
AU2006236637B2
(en)
*
|
2005-04-15 |
2012-09-06 |
Merck Sharp & Dohme Corp. |
Methods and compositions for treating or preventing cancer
|
CA2789262C
(en)
|
2005-04-28 |
2016-10-04 |
Proteus Digital Health, Inc. |
Pharma-informatics system
|
GB0510390D0
(en)
|
2005-05-20 |
2005-06-29 |
Novartis Ag |
Organic compounds
|
WO2007035716A2
(en)
|
2005-09-16 |
2007-03-29 |
Raptor Pharmaceutical Inc. |
Compositions comprising receptor-associated protein (rap) variants specific for cr-containing proteins and uses thereof
|
RU2008116314A
(ru)
|
2005-09-27 |
2009-11-10 |
Новартис АГ (CH) |
Соединения карбоксамина и их применение для лечения hdac-зависимых заболеваний
|
US20070144968A1
(en)
*
|
2005-10-05 |
2007-06-28 |
Cristian Fazioni |
Separation of fulvestrant isomers
|
EP2275103B1
(de)
|
2005-11-21 |
2014-04-23 |
Novartis AG |
mTOR-Inhibitoren in der Behandlung endokriner Tumore
|
US20070197488A1
(en)
*
|
2005-11-29 |
2007-08-23 |
Olaf Peters |
Prodrugs of ERbeta-selective substances, process for their production, and pharmaceutical compositions that contain these compounds
|
US20070123500A1
(en)
*
|
2005-11-29 |
2007-05-31 |
Gerd Mueller |
Prodrugs of ERbeta-selective substances, processes for their preparation and pharmaceutical compositions comprising these compounds
|
US20070135375A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Sulfamoyl sulfonate prodrugs
|
US20070135399A1
(en)
*
|
2005-11-30 |
2007-06-14 |
Ralf Wyrwa |
Heteroaromatic sulphonamide prodrugs
|
GB0605120D0
(en)
|
2006-03-14 |
2006-04-26 |
Novartis Ag |
Organic Compounds
|
EP2004163B1
(de)
|
2006-04-05 |
2014-09-17 |
Novartis Pharma AG |
Kombination von everolimus und vinorelbin
|
EP2314297A1
(de)
|
2006-04-05 |
2011-04-27 |
Novartis AG |
Kombinationen aus bcr-abl/c-kit/pdgf-r tk-Hemmern zu Krebsbehandlung
|
KR20090007635A
(ko)
|
2006-05-09 |
2009-01-19 |
노파르티스 아게 |
철 킬레이터 및 항-신생물 약제를 포함하는 조합물 및 그의용도
|
ATE502943T1
(de)
|
2006-09-29 |
2011-04-15 |
Novartis Ag |
Pyrazolopyrimidine als pi3k-lipidkinasehemmer
|
US8916552B2
(en)
|
2006-10-12 |
2014-12-23 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
WO2008044045A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
PE20090519A1
(es)
|
2007-02-15 |
2009-05-29 |
Novartis Ag |
Composicion farmaceutica que contiene n-hidroxi-3-[4-[[[2-(2-metil-1h-indol-3-il)-etil]-amino]-metil]-fenil]-2e-2-propenamida
|
US20100174101A1
(en)
*
|
2007-09-24 |
2010-07-08 |
Xi'an Liband Pharmaceutical Co., Ltd. |
Process for the manufacture of 7-alpha-[9-(4,4,5,5,5-penta fluoropentylsulphinyl) nonyl]estra-1,3,5-(10)- triene-3,17-beta-diol
|
US20090082323A1
(en)
*
|
2007-09-25 |
2009-03-26 |
Protia, Llc |
Deuterium-enriched fulvestrant
|
EA017385B1
(ru)
|
2007-10-16 |
2012-12-28 |
Репрос Терапьютикс Инк. |
Применение транс-кломифена для снижения концентрации глюкозы в сыворотке
|
EP2070941A1
(de)
|
2007-12-14 |
2009-06-17 |
Bayer Schering Pharma Aktiengesellschaft |
Stereoselektive Synthese von selektiven negativen Regulatoren von Östrogenrezeptoren
|
JP2011514349A
(ja)
|
2008-03-07 |
2011-05-06 |
サイドース・エルエルシー |
フルベストラント配合物
|
BRPI0908603A2
(pt)
|
2008-03-24 |
2020-08-18 |
Novartis Ag |
inibidores de metaloprotease de matriz com base em arilsulfonamida.
|
EP2628726A1
(de)
|
2008-03-26 |
2013-08-21 |
Novartis AG |
Auf Hydroxamat basierende Hemmer von Deacetylasen B
|
US8063249B1
(en)
|
2008-04-25 |
2011-11-22 |
Olema Pharmaceuticals, Inc. |
Substituted triphenyl butenes
|
CN102227441A
(zh)
*
|
2008-10-15 |
2011-10-26 |
斯索恩有限公司 |
制备氟维司群的方法和中间体
|
WO2010083617A1
(en)
|
2009-01-21 |
2010-07-29 |
Oncalis Ag |
Pyrazolopyrimidines as protein kinase inhibitors
|
PT2391366E
(pt)
|
2009-01-29 |
2013-02-05 |
Novartis Ag |
Benzimidazoles substituídos para o tratamento de astrocitomas
|
PL2398500T3
(pl)
|
2009-02-20 |
2019-09-30 |
2-Bbb Medicines B.V. |
System dostarczania leków na bazie glutationu
|
KR101741629B1
(ko)
|
2009-05-06 |
2017-05-31 |
라보라토리 스킨 케어, 인크. |
활성제-칼슘 포스페이트 입자 복합체를 포함하는 피부 전달 조성물 및 이들을 이용하는 방법
|
EP2258375A1
(de)
|
2009-06-04 |
2010-12-08 |
Bayer Schering Pharma Aktiengesellschaft |
17B-alkyl-17alpha-oxy-estratriene
|
WO2010151133A1
(en)
|
2009-06-25 |
2010-12-29 |
Erasmus University Medical Center Rotterdam |
Methods for establishing and predicting resistance to endocrine therapy using an mirna profile
|
ES2475945T3
(es)
|
2009-06-26 |
2014-07-11 |
Novartis Ag |
Derivados imidazolidin-2 -ona 1,3-disustituida como inhibidores de CYP 17
|
US8389526B2
(en)
|
2009-08-07 |
2013-03-05 |
Novartis Ag |
3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
|
BR112012003262A8
(pt)
|
2009-08-12 |
2016-05-17 |
Novartis Ag |
compostos de hidrazona heterocíclica e seus usos para tratar câncer e inflamação
|
KR20120089463A
(ko)
|
2009-08-20 |
2012-08-10 |
노파르티스 아게 |
헤테로시클릭 옥심 화합물
|
US20120149661A1
(en)
|
2009-08-26 |
2012-06-14 |
Novartis Ag |
Tetra-substituted heteroaryl compounds and their use as mdm2 and/or mdm4 modulators
|
WO2011029915A1
(en)
|
2009-09-10 |
2011-03-17 |
Novartis Ag |
Ether derivatives of bicyclic heteroaryls
|
KR101398772B1
(ko)
|
2009-11-04 |
2014-05-27 |
노파르티스 아게 |
Mek 억제제로서 유용한 헤테로시클릭 술폰아미드 유도체
|
CN102712648A
(zh)
|
2009-11-25 |
2012-10-03 |
诺瓦提斯公司 |
双环杂芳基的与苯稠合的6元含氧杂环衍生物
|
BR112012013735A2
(pt)
|
2009-12-08 |
2019-09-24 |
Novartis Ag |
derivados heterocícilicos de sulfonamida
|
CU24130B1
(es)
|
2009-12-22 |
2015-09-29 |
Novartis Ag |
Isoquinolinonas y quinazolinonas sustituidas
|
US8440693B2
(en)
|
2009-12-22 |
2013-05-14 |
Novartis Ag |
Substituted isoquinolinones and quinazolinones
|
US20130085161A1
(en)
|
2010-06-17 |
2013-04-04 |
Novartis Ag |
Piperidinyl substituted 1,3-dihydro-benzoimidazol-2-ylideneamine derivatives
|
CN102947274A
(zh)
|
2010-06-17 |
2013-02-27 |
诺瓦提斯公司 |
联苯基取代的1,3-二氢-苯并咪唑-2-亚基胺衍生物
|
DE102010030538A1
(de)
|
2010-06-25 |
2011-12-29 |
Bayer Schering Pharma Aktiengesellschaft |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
UA112517C2
(uk)
|
2010-07-06 |
2016-09-26 |
Новартіс Аг |
Тетрагідропіридопіримідинові похідні
|
CN103108871B
(zh)
|
2010-09-16 |
2014-09-10 |
诺华股份有限公司 |
17α-羟化酶/C17,20-裂合酶抑制剂
|
MX356514B
(es)
|
2011-01-20 |
2018-05-30 |
Univ Texas |
Marcadores de formación de imagen por resonancia magnética, sistemas de suministro y extracción, y métodos de fabricación y uso de los mismos.
|
EP2673277A1
(de)
|
2011-02-10 |
2013-12-18 |
Novartis AG |
[1, 2, 4] triazolo [4, 3]pyridazinverbindungen als inhibitoren dec-met-tyrosinkinase
|
CN103492390A
(zh)
|
2011-03-08 |
2014-01-01 |
诺瓦提斯公司 |
氟苯基双环杂芳基化合物
|
BR112013027395A2
(pt)
|
2011-04-28 |
2017-01-17 |
Novartis Ag |
inibidores de 17alfa-hidroxilase/c17,20-liase
|
EA201391820A1
(ru)
|
2011-06-09 |
2014-12-30 |
Новартис Аг |
Гетероциклические сульфонамидные производные
|
WO2012175487A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Cyclohexyl isoquinolinone compounds
|
WO2012175520A1
(en)
|
2011-06-20 |
2012-12-27 |
Novartis Ag |
Hydroxy substituted isoquinolinone derivatives
|
EP2723740A1
(de)
|
2011-06-27 |
2014-04-30 |
Novartis AG |
Feststoffformen und salze von tetrahydro-pyrido-pyrimidin- derivaten
|
AU2012310168B2
(en)
|
2011-09-15 |
2015-07-16 |
Novartis Ag |
6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase
|
CN104080787B
(zh)
|
2011-11-29 |
2016-09-14 |
诺华股份有限公司 |
吡唑并吡咯烷化合物
|
DE102011087987A1
(de)
|
2011-12-08 |
2013-06-13 |
Bayer Intellectual Property Gmbh |
6,7-Dihydro-5H-benzo[7]annulen-Derivate, Verfahren zu ihrer Herstellung, pharmazeutische Präparate die diese enthalten, sowie deren Verwendung zur Herstellung von Arzneimitteln
|
US9018244B2
(en)
|
2011-12-16 |
2015-04-28 |
Olema Pharmaceuticals, Inc. |
Benzopyran compounds, compositions and uses thereof
|
CN104011045B
(zh)
|
2011-12-22 |
2016-08-24 |
诺华股份有限公司 |
二氢苯并噁嗪和二氢吡啶并噁嗪衍生物
|
EP2794594A1
(de)
|
2011-12-22 |
2014-10-29 |
Novartis AG |
Chinolinderivate
|
CN104125954A
(zh)
|
2011-12-23 |
2014-10-29 |
诺华股份有限公司 |
用于抑制bcl2与结合配偶体相互作用的化合物
|
US20140357633A1
(en)
|
2011-12-23 |
2014-12-04 |
Novartis Ag |
Compounds for inhibiting the interaction of bcl2 with binding partners
|
EP2794590A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
BR112014015442A8
(pt)
|
2011-12-23 |
2017-07-04 |
Novartis Ag |
compostos e composições para inibir a interação de bcl2 com parceiros de ligação
|
EP2794588A1
(de)
|
2011-12-23 |
2014-10-29 |
Novartis AG |
Verbindungen zur hemmung der interaktion von bcl2 mit bindungspartnern
|
US8815926B2
(en)
|
2012-01-26 |
2014-08-26 |
Novartis Ag |
Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases
|
JP2015505562A
(ja)
|
2012-01-31 |
2015-02-23 |
ノバルティス アーゲー |
Rtk阻害剤と抗エストロゲン剤との組合せ、およびがん治療のためのその使用
|
JP2015508825A
(ja)
|
2012-02-29 |
2015-03-23 |
レプロス セラピューティクス インコーポレイティド |
アンドロゲン欠乏症を治療するための併用療法
|
US11179468B2
(en)
|
2012-04-09 |
2021-11-23 |
Eagle Pharmaceuticals, Inc. |
Fulvestrant formulations
|
EP2855483B1
(de)
|
2012-05-24 |
2017-10-25 |
Novartis AG |
Pyrrolopyrrolidinonverbindungen
|
HUE033380T2
(en)
|
2012-10-02 |
2017-11-28 |
Gilead Sciences Inc |
Inhibitors of histone demethylases
|
JP2016027000A
(ja)
*
|
2012-10-09 |
2016-02-18 |
学校法人早稲田大学 |
ステロイド化合物及びこれを含有する医薬
|
US9315540B2
(en)
|
2012-10-22 |
2016-04-19 |
Intas Pharmaceuticals Ltd. |
Process for the preparation of fulvestrant
|
TW201422625A
(zh)
|
2012-11-26 |
2014-06-16 |
Novartis Ag |
二氫-吡啶并-□衍生物之固體形式
|
WO2014115077A1
(en)
|
2013-01-22 |
2014-07-31 |
Novartis Ag |
Substituted purinone compounds
|
US9556180B2
(en)
|
2013-01-22 |
2017-01-31 |
Novartis Ag |
Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction
|
WO2014128612A1
(en)
|
2013-02-20 |
2014-08-28 |
Novartis Ag |
Quinazolin-4-one derivatives
|
CN105263906B
(zh)
|
2013-02-27 |
2018-11-23 |
吉利德科学公司 |
组蛋白脱甲基酶的抑制剂
|
EP2987799B1
(de)
*
|
2013-04-18 |
2020-04-08 |
Xi'an Libang Pharmaceutical Technology Co.,ltd. |
Esterderivate von 7-alpha-[9-(4,4,5,5,5-pentafluorpentylsulphinyl)nonyl]oestra-1,3,5(10)-trien-3,17beta-diol mit antitumoraktivität und herstellungsverfahren dafür
|
US20150018376A1
(en)
|
2013-05-17 |
2015-01-15 |
Novartis Ag |
Pyrimidin-4-yl)oxy)-1h-indole-1-carboxamide derivatives and use thereof
|
WO2014203129A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Combinations of benzopyran compounds, compositions and uses thereof
|
WO2014203132A1
(en)
|
2013-06-19 |
2014-12-24 |
Olema Pharmaceuticals, Inc. |
Substituted benzopyran compounds, compositions and uses thereof
|
UY35675A
(es)
|
2013-07-24 |
2015-02-27 |
Novartis Ag |
Derivados sustituidos de quinazolin-4-ona
|
US9227969B2
(en)
|
2013-08-14 |
2016-01-05 |
Novartis Ag |
Compounds and compositions as inhibitors of MEK
|
WO2015022663A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
WO2015022664A1
(en)
|
2013-08-14 |
2015-02-19 |
Novartis Ag |
Compounds and compositions as inhibitors of mek
|
AU2014321419B2
(en)
|
2013-09-22 |
2017-06-15 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
CA2936783A1
(en)
|
2014-01-15 |
2015-07-23 |
Novartis Ag |
Pharmaceutical combinations
|
WO2015148867A1
(en)
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AU2015241022A1
(en)
|
2014-03-31 |
2016-10-27 |
Gilead Sciences, Inc. |
Inhibitors of histone demethylases
|
CN103965280B
(zh)
*
|
2014-05-21 |
2016-04-20 |
天津孚音生物科技发展有限公司 |
一种氟维司群中间体的制备方法
|
CN103980336B
(zh)
*
|
2014-05-21 |
2016-10-05 |
天津孚音生物科技发展有限公司 |
一种新的氟维司群的合成方法
|
WO2015181116A1
(en)
|
2014-05-26 |
2015-12-03 |
Crystal Pharma, S.A.U. |
Process and intermediades for the preparation of 7-alkylated steroids
|
US9802941B2
(en)
|
2014-08-27 |
2017-10-31 |
Gilead Sciences, Inc. |
Compounds and methods for inhibiting histone demethylases
|
JP2018527362A
(ja)
|
2015-09-11 |
2018-09-20 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. |
置換されたヘテロアリール化合物および使用方法
|
LT3355884T
(lt)
|
2015-10-01 |
2021-07-26 |
Olema Pharmaceuticals, Inc. |
Tetrahidro-1h-pirido[3,4-b]indolo antiestrogeniniai vaistai
|
AU2016352592B2
(en)
|
2015-11-10 |
2023-04-27 |
Paracrine Therapeutics Ab |
Treatment of ER-negative breast cancer with an PDGF-CC inhibitor and an anti estrogen
|
US20170166551A1
(en)
|
2015-12-09 |
2017-06-15 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective estrogen receptor downregulator compounds
|
WO2018017410A1
(en)
|
2016-07-22 |
2018-01-25 |
Eli Lilly And Company |
Combination therapy of abemaciclib and a pi3 kinase/mtor dual inhibitor for use in the treatment of breast cancer
|
WO2018081168A2
(en)
|
2016-10-24 |
2018-05-03 |
The Board Of Trustees Of The University Of Illinois |
Benzothiophene-based selective mixed estrogen receptor downregulators
|
MX2019008158A
(es)
|
2017-01-06 |
2019-12-09 |
G1 Therapeutics Inc |
Terapia de combinacion para el tratamiento del cancer.
|
US10683297B2
(en)
|
2017-11-19 |
2020-06-16 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
AU2017444054B2
(en)
|
2017-12-21 |
2021-10-07 |
Hefei Institutes Of Physical Science, Chinese Academy Of Sciences |
Class of pyrimidine derivative kinase inhibitors
|
AU2019209960B2
(en)
|
2018-01-20 |
2023-11-23 |
Sunshine Lake Pharma Co., Ltd. |
Substituted aminopyrimidine compounds and methods of use
|
US20220395553A1
(en)
|
2019-11-14 |
2022-12-15 |
Cohbar, Inc. |
Cxcr4 antagonist peptides
|
CN115135649A
(zh)
|
2020-03-10 |
2022-09-30 |
正大天晴药业集团股份有限公司 |
包括吡啶并[1,2-a]嘧啶酮化合物的药物组合
|
IT202100003176A1
(it)
|
2021-02-12 |
2022-08-12 |
Farmabios Spa |
Processo per la preparazione di fulvestrant
|
CN114716496B
(zh)
*
|
2022-04-29 |
2024-04-02 |
香港中文大学(深圳) |
氟维司群衍生物及氟维司群衍生物制备方法和应用
|
CN116535454A
(zh)
*
|
2023-04-28 |
2023-08-04 |
香港中文大学(深圳) |
氟维司群类化合物及其制备方法和应用
|